Continued growth “despite Covid-19”

money stock level up financial
AFT Pharmaceuticals has announced growth across its portfolio of OTC and prescription medicines in its half-year financial results AFT Pharmaceuticals reports “continuing good progress” in commercialising its Maxigesic pain medication in international markets, despite Covid-19 challenges. Group operating revenue for the six months to 30 September 2020 grew by 4% to NZ$48.8 million from NZ$46.9

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous World news wrapup: 19 November 2020
Next Clinical tips: Advancements in the management of erectile dysfunction